Our team found this extremely interesting.  Apparently this product has been available to Goverment and Department of Defense Employees since about 2004.  Does the Gov’t know the secret to stop outbreaks.  The research about Virista is below.

 

OFFICIAL IND PHASE II CLINICAL TRIAL RESULTS
Approved FDA Clinical Study (Phase II) shows Virista’s ingredients prevent or delay outbreaks and significantly reduces healing time on sores.
FDA Phase II placebo controlled clinical trials performed under the direction of Dr. Morris Shelanski, at Product Investigations, Inc., conclude that Virista provides the following benefits:
 
  1. Promotes faster healing by two days.
  2. Prevents outbreaks against UV-light.
  3. Delays outbreaks.
  4. Results in smaller sore sizes.
  5. Has no side effects.
Product Investigations, Inc., has been involved in hundreds of FDA clinical tests for some of the world’s largest pharmaceutical companies.
     

RESEARCH CONDUCTED BY PROCTER & GAMBLE
In Vitro and In Vivo Evaluation of the Activity of Stannous Compounds Against Herpes Simplex Virus
“Treatment with SnF2 or Sn Gluconate resulted in reduction of recurrences compared to untreated controls. These results are encouraging and suggest that stannous compounds might be useful in the treatment or prevention of HSV infections. Further studies are needed to determine the mechanism of action of this unique class of anti-herpes drugs.”SOURCE: Reising S.F., Bourne K.Z., Bourne N., Awar F. El., Pyles R., Majetti S. and Stanberry L.R., In Vitro and In Vivo Evaluation of the Activity of Stannous Compounds Against Herpes Simplex Virus, Division of Infectious Diseases, Children’s Hospital Research Foundation and Procter & Gamble, Cincinnati, Ohio, Antiviral Research, Vol. 37, No.3, March 1998.Why this is important:
This study suggests Virista’s Stannous Compounds might be useful in treatment or prevention of herpes simplex outbreaks.
     

RESEARCH CONDUCTED AT THE UNIVERSITY OF MANITOBA
In-Vitro Studies Reveal Virista is Virucidal at Therapeutic Doses
Studies conducted at the University of Manitoba, Canada, demonstrate that therapeutic doses of Virista appear to have a direct effect on the herpes simplex virus. Data shows that Virista ingredients possess both virucidal and antiviral properties.

 

   
 

NATIONAL MEDICAL JOURNALS CONTAINING VIRISTA STUDIES

Clinical Effect of Virista Gel Preparation on Herpes Zoster Virus Outbreak
Recent studies have shown Virista to successfully control several strains of the herpes virus in humans. In one study, the purpose was to evaluate the clinical efficacy of Virista topical gel on reduction of pain and itch associated with trigeminal dermatomal reactivation of varicella zoster virus, commonly known as shingles.The study involved twelve patients; six in one group having chronic pain and active shingles less than 3 days, and six patients in another group having trigeminal pain (post herpetic neuralgia) without lesions from previous shingles of less than 1 year. Each patient applied the Virista topical gel as needed to control their pain and itching.Results demonstrated that the Virista gel relieved the pain and itching in both groups for an average of 3 hours after each application. Furthermore, rashes and blisters associated with shingles in the active lesion group resolved in less than 3 weeks with little or no scarring and without post herpetic pain.

This study confirmed that Virista gel applications during varicella reactivationmay prevent the severity of nerve damage that often leads to long-term post herpetic neuralgia in about 10% of patients. It further indicated that clinical application of Virista gel can benefit patients who suffer from a reactivation of a trigeminal varicella zoster virus infection.

SOURCE: Journal of Aesthetic Dermatology and Cosmetic Surgery, Winter Issue, 1999.

Treatment of Herpes Simplex Labialis with Virista Stannous Compounds
Two controlled double blind studies designed to assess the antiviral properties of Virista have been presented. Their results demonstrate that the antimicrobial properties of Virista gel that inhibit bacteria, also inhibit the herpes viruses. Both studies confirm that the topical application of the proprietary preparation of Virista gel for Herpes Simplex Labialis: limit full outbreaks; accelerate healing time; reduce the number of recurrences, and alleviate patient discomfort.Although the data in this paper are preliminary, the findings are significant enough to warrant additional research on the use of Virista gel as a topical treatment for the herpes simplex virus.SOURCE: Cosmetic Dermatology, Vol. 12, No. 4, April 1999.